Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trellus Health PLC ( (GB:TRLS) ) has provided an update.
Trellus Health has issued 16,454,134 new ordinary shares following the conversion of £50,000 of principal under the second tranche of its secured convertible loan notes. The new shares are expected to be admitted to trading on AIM around 5 March 2026, increasing the company’s issued share capital and total voting rights to 225,173,495 ordinary shares, a figure shareholders can use to assess disclosure thresholds under FCA rules.
The conversion modestly reduces the company’s outstanding loan note debt while marginally diluting existing shareholders through the expanded equity base. The updated share count clarifies Trellus Health’s capital structure and provides a new reference point for investors monitoring changes in significant shareholdings and corporate control metrics.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare technology company listed on AIM that provides value-based digital solutions to help people with complex chronic conditions manage their health. Its Trellus Elevate platform combines data analytics, proprietary resilience-based methodology, and expert coaching to support patients, initially focusing on high-cost gastrointestinal diseases such as inflammatory bowel disease.
Average Trading Volume: 6,549,502
Technical Sentiment Signal: Hold
Current Market Cap: £1.36M
For detailed information about TRLS stock, go to TipRanks’ Stock Analysis page.